Inmode
Open
$13.46
Prev. Close
$13.46
High
$13.48
Low
$13.45
Market Snapshot
$852.18M
9.8
2.37
$394.82M
660
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. The company is headquartered in Yokneam, Northern (Hazafon) and currently employs 660 full-time employees. The company went IPO on 2019-08-08. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. The company is headquartered in Yokneam, Northern (Hazafon) and currently employs 660 full-time employees. The company went IPO on 2019-08-08. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.